Summary

Responses to oral antiplatelet therapy between patients are variable; thus, bedside assessment has been regarded as an opportunity for individualizing therapy for patients following coronary stent implantation to ensure the optimal platelet inhibition is obtained. The Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy [ARCTIC; NCT00827411; Collet JP et al. N Engl J Med 2012] trial evaluated platelet function testing with antiplatelet dose adjustment in suboptimal responders compared with standard of care.